3D MOLECULAR DOCKING COMBINED WITH AI-DRIVEN VIRTUAL SCREENING TO REPURPOSE FDA-APPROVED DRUGS FOR RARE NEURODEGENERATIVE DISEASES. Int. J. Exp. Biol. 2024;2(01):50-73. Accessed April 30, 2026. https://ijeb.online/index.php/IJEB/article/view/23